Cannabis Stocks Rally on Trump Rescheduling Signal

Cannabis stocks posted broad gains following reports that President Trump plans to advance marijuana rescheduling from Schedule I to Schedule III under the Controlled Substances Act. The move represents a continuation of the Biden administration's DEA rescheduling process, which has been under review since 2022.

The rescheduling development carries substantial financial implications for cannabis operators currently handicapped by Section 280E tax restrictions. Under Schedule I classification, marijuana businesses cannot deduct standard operating expenses, creating effective tax rates exceeding 70% in many cases. Schedule III status would eliminate these restrictions, potentially adding hundreds of millions in cash flow across the sector.

Major multi-state operators stand to benefit most significantly from the tax relief. Companies like Curaleaf, Green Thumb Industries, and Trulieve have collectively paid over $1 billion in excess taxes due to 280E limitations over recent years. The rescheduling could immediately improve EBITDA margins by 15-25 percentage points for profitable operators, while providing crucial breathing room for companies still burning cash.

The regulatory shift also opens pathways for institutional investment and traditional banking services that remain largely off-limits under Schedule I. Federal rescheduling removes key compliance barriers for pension funds, mutual funds, and other institutional capital that has avoided the sector due to federal prohibition concerns.

While rescheduling falls short of full legalization, it represents the most significant federal cannabis policy advancement in decades. The move requires final DEA approval and public comment periods, but Trump's endorsement accelerates a process that faced uncertainty under previous political dynamics. Cannabis operators now face a fundamentally altered regulatory landscape that could drive consolidation and expansion as access to capital and banking services normalizes.